CIPN is a debilitating condition in which chemotherapy drugs damage the peripheral nerves, most often those serving the hands and feet. Patients typically experience numbness, tingling, burning pain, and loss of fine motor control. In severe cases, the symptoms persist for months or years after treatment ends, and there is currently no approved drug that reliably prevents or reverses the damage. Because paclitaxel, a mainstay taxane chemotherapy for breast cancer, is among the most neuropathy-inducing agents in clinical use, the search for a practical preventive measure has become a major priority in supportive oncology care.

The logic behind cryotherapy is elegantly straightforward. When a patient’s hands and feet are cooled during the infusion of chemotherapy, blood vessels in those extremities constrict, a process known as vasoconstriction. This reduces local blood flow, which in turn limits the amount of drug delivered to the small nerve fibers in the fingers and toes. Cooling also slows metabolic activity in nerve tissue and may reduce the cellular uptake of taxane molecules, further protecting the delicate axons that transmit sensation. The result is a physical barrier of sorts—cold-induced starvation of the drug at precisely the sites where neuropathy strikes first.

To test whether this mechanism translates into real clinical benefit, the research team searched six major databases—Scopus, PubMed/MEDLINE, ProQuest, ScienceDirect, SAGE Journals, and the Cochrane Library—from inception to July 17, 2025, without imposing date limits or restricting inclusion to randomized designs. The protocol was prospectively registered in PROSPERO before the final search update, a practice that helps guard against selective reporting. The team ultimately included fourteen studies: twelve randomized controlled trials and two retrospective cohort studies, all involving breast cancer patients receiving paclitaxel or nab-paclitaxel with cryotherapy as the primary preventive intervention.

The headline findings come from the comparative double-arm analyses, which directly compared cryotherapy against no cooling or alternative care. Patients who used cryotherapy had roughly 55 percent lower odds of developing moderate to severe neuropathy, measured as CTCAE Grade 2 or higher, with a relative risk of 0.45 and a 95 percent confidence interval of 0.27 to 0.77, a statistically significant result. Sensory neuropathy—the numbness and tingling that most often impair daily function—was reduced even more dramatically, with a relative risk of 0.35. On a second validated instrument, the Patient Neurotoxicity Questionnaire, the risk of reaching grade D or higher total scores fell to just 0.24 of the comparator risk, again statistically significant. Motor neuropathy, by contrast, showed no significant reduction, a finding the authors note honestly rather than glossing over.

Statistical heterogeneity across the comparative trials was low to moderate, which lends credibility to the pooled estimates. Risk of bias was assessed using the Cochrane RoB 2 tool for randomized studies and ROBINS-I for the non-randomized cohorts, while the certainty of the evidence was graded with the GRADE framework. This methodological rigor matters, because meta-analyses of supportive-care interventions are frequently criticized for combining heterogeneous protocols and outcome measures. Here, the authors took the additional step of separating comparative outcomes from single-arm proportions, treating the latter as very low-certainty, purely descriptive evidence rather than folding them into the efficacy estimates.

That separation proved important. The single-arm studies, which reported neuropathy incidence in cryotherapy users without a control group, yielded a pooled CTCAE Grade 2 or higher proportion of 0.20, but with high heterogeneity and no comparator, this figure cannot demonstrate efficacy. Similarly, pooled tolerability outcomes—any adverse event at 19 percent, cold intolerance at 16 percent, and discontinuation of cryotherapy due to side effects at just 2 percent—are non-comparative and highly heterogeneous. The authors explicitly caution that these descriptive estimates should not be interpreted as proof of safety or effectiveness, a level of statistical humility that is refreshingly rare in the field.

Two clinically crucial outcomes remain unresolved. Chemotherapy dose reduction, which matters because neuropathy often forces oncologists to cut treatment short, showed a relative risk of 0.43 in favor of cryotherapy, but this estimate rested on only two studies with a confidence interval crossing unity and a p-value of 0.109. Treatment discontinuation due to neuropathy showed an even larger apparent benefit, with a relative risk of 0.22, yet the p-value of 0.163 and wide confidence intervals mean the result is underpowered and inconclusive. These are precisely the outcomes that would matter most to patients and oncologists alike, and the authors are candid that larger trials are needed before any firm claims can be made.

The practical appeal of cryotherapy is hard to overstate. Unlike pharmacological candidates such as duloxetine, which carries its own side-effect profile, cooling devices are inexpensive, non-invasive, and require no systemic exposure. The low discontinuation rate of 2 percent suggests that most patients can tolerate the discomfort of wearing frozen gloves and socks for the duration of an infusion, even if cold intolerance affects roughly one in six. For a therapy that could spare a substantial fraction of breast cancer patients from chronic numbness and pain, the risk-benefit calculus appears favorable on its face.

Still, the authors urge cautious clinical interpretation. The evidence base, while promising, is built on trials with variable cooling protocols, differing outcome instruments, and limited power for the outcomes that matter most. Standardized intervention parameters—exact temperatures, duration of cooling, and timing relative to drug infusion—have yet to be established, and until large, well-designed randomized trials confirm the effects on dose intensity and treatment completion, cryotherapy should be viewed as a promising but not yet definitive preventive strategy. What the current analysis does establish is that the biological rationale is sound, the comparative signal is consistent, and the barrier to testing at scale is remarkably low. In a field where patients have long been told to simply endure the tingling, the prospect that a pair of frozen gloves might protect the nerves that matter most is a finding worth taking seriously.

Subject of Research: Cryotherapy for preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with paclitaxel

Article Title: Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis

Article References: Prajoko, Y. W., Tjandra, K. C., Respati, D. R. P., Ar, A., Bulandari, B. L. A., Aryasatya, D. P., Rahmani, K., & Bima, R. C. S. (2026). Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16971-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16971-7

Keywords: cryotherapy, chemotherapy-induced peripheral neuropathy, breast cancer, paclitaxel, nab-paclitaxel, meta-analysis, systematic review, sensory neuropathy, supportive oncology, taxane chemotherapy, CTCAE, nerve protection

The trial, published in Cancer Reports, evaluated a biweekly regimen of gemcitabine plus nab-paclitaxel, a two-drug combination widely known by the abbreviation GnP. In its conventional form, GnP is administered on Days 1, 8, and 15 of a 28-day cycle, a schedule validated by the landmark MPACT trial, which demonstrated a survival advantage over gemcitabine alone in patients with metastatic disease. The Osaka team instead delivered both agents on Days 1 and 15 only, at the standard doses of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, reasoning that fewer infusions per cycle might ease the burden on older bodies without sacrificing efficacy. Retrospective studies of biweekly GnP in broader populations had already hinted at feasibility, reporting median overall survival of around 10 months, but prospective data in patients aged 75 and older had been essentially absent.

Seventeen patients with unresectable pancreatic cancer, either locally advanced or metastatic, enrolled between August 2019 and March 2021. Their median age was 77, with a range of 75 to 81 years, and the vast majority, 76.5 percent, had metastatic disease. All were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, indicating they were still fully ambulatory or capable of light activity, along with adequate blood counts, liver function, and kidney function. The researchers also used the Geriatric-8 screening tool, an eight-item questionnaire designed to capture vulnerabilities that standard performance measures miss, and scores ranged widely from 6 to 17, a reminder that chronological age conceals substantial heterogeneity in physical reserve. Notably, 12 of the 17 patients had hypertension, 7 had hyperlipidemia, and 6 had diabetes, reflecting the comorbidity burden typical of this age group.

The trial employed Simon’s two-stage minimax design, a statistical framework that allows early stopping if a regimen appears unacceptably ineffective. With an expected overall response rate of 30 percent and a rejection threshold of 7 percent, the study required 18 evaluable patients. Seven patients were assessed in the first stage, and once at least one tumor response was confirmed, the trial advanced to its second stage. Planned enrollment was 20 patients, but accrual ended at 17 due to an unstable supply of nab-paclitaxel during the study period, a practical setback that the authors acknowledge constrained the final statistical power of the efficacy analysis.

Despite the smaller-than-planned cohort, the efficacy signals were striking. At the March 31, 2023 data cutoff, with a median follow-up of 16.8 months, the confirmed overall response rate reached 47.1 percent, with all eight responders achieving partial responses. The 95 percent confidence interval ranged from 23.0 to 72.2 percent, comfortably exceeding the prespecified expectation of 30 percent. The disease control rate, which combines complete and partial responses with stable disease, stood at 82.4 percent. Median overall survival was 16.8 months and median progression-free survival was 8.3 months, figures that sit squarely within the range reported for standard three-times-per-cycle GnP in pivotal trials, including the GENERATE (JCOG1611) trial in Japanese patients, which reported median overall survival of 17.1 months in a cohort capped at age 75. One- and two-year survival rates were 58.8 and 29.4 percent, respectively.

Safety results, however, temper any temptation toward celebration. Every patient experienced at least one adverse event, and grade 3 or higher events of any cause occurred in 52.9 percent of the cohort, with treatment-related severe events in 29.4 percent. The most common toxicities of any grade included anemia in 88.2 percent, alopecia in 88.2 percent, decreased white blood cell count in 76.5 percent, fatigue in 76.5 percent, and peripheral sensory neuropathy in 64.7 percent. Among treatment-related severe events, neutropenia led at 17.6 percent. Seven patients experienced serious adverse events, two of which were judged related to the study drugs. No treatment-related deaths occurred, and no patient died from any adverse event during the study, an outcome the investigators emphasize as meaningful in such a fragile population.

Treatment delivery also revealed the limits of any fixed schedule in older adults. Although the biweekly design meant fewer planned infusions, 11 of 17 patients, 64.7 percent, still required at least one dose reduction, most often of nab-paclitaxel, whose median relative dose intensity fell to 87.3 percent compared with 100 percent for gemcitabine. Three patients discontinued protocol treatment because of adverse events: two for peripheral sensory neuropathy and one for grade 2 interstitial pneumonia, all of whom recovered and moved on to subsequent therapy. The authors argue that the frequency of dose reduction underscores that individualized dose adjustment remains essential even under a deliberately gentler schedule, and they suggest that clinicians may reasonably consider starting at a reduced dose in patients with greater geriatric vulnerability, though the study cannot define precise criteria for that decision.

An intriguing exploratory finding was that survival was actually shorter in the four patients with locally advanced disease than in the thirteen with metastatic disease, a reversal of the usual prognostic pattern. The investigators attribute this largely to the very small subgroup size, which makes estimates unstable, and to baseline characteristics suggesting that the locally advanced patients tended to have poorer performance status and lower Geriatric-8 scores. Exploratory analyses confirmed that patients with performance status 0 fared better than those with status 1, while the Geriatric-8 stratification was too small to interpret. What was unambiguous, however, was the role of subsequent treatment: 14 of the 17 patients, 82.4 percent, went on to receive further systemic therapy after stopping the study regimen, most commonly the oral fluoropyrimidine S-1 or fluorouracil plus nanoliposomal irinotecan, and previous research has consistently shown that effective second-line therapy extends survival in advanced pancreatic cancer.

Beyond the numbers, the study raises a question that oncologists increasingly regard as central to geriatric care: the concept of time toxicity, the share of a patient’s remaining life consumed by treatment itself. Real-world data suggest that pancreatic cancer patients receiving palliative chemotherapy spend roughly 10 percent of their remaining life on healthcare-related activities. A biweekly schedule involves fewer clinic visits per cycle than the conventional regimen, and while this trial did not measure time toxicity prospectively, the authors argue the potential convenience benefit deserves rigorous comparative evaluation. They are equally candid about the study’s limitations: it was single-center, single-arm, and small, enrolled only Japanese patients, excluded frail patients through strict performance and organ-function criteria, and did not perform comprehensive geriatric assessment. Still, in a disease where evidence for patients over 75 has long been extrapolated from younger cohorts, the trial delivers something genuinely scarce: prospective, age-specific data showing that a thoughtfully modified regimen can achieve response rates and survival figures comparable to those of standard protocols, and that, with careful monitoring, many older adults can tolerate and benefit from active combination chemotherapy rather than being consigned to monotherapy or supportive care alone.

Subject of Research: Biweekly gemcitabine plus nab-paclitaxel as first-line therapy for pancreatic cancer patients aged 75 and older

Article Title: Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Article References: Ikezawa, K., Imai, T., Takada, R., Yamai, T., Fukutake, N., Urabe, M., Kai, Y., Mukai, K., Nakabori, T., & Ohkawa, K. (2026). Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer. Cancer Reports, 9(9), Article e70691. https://doi.org/10.1002/cnr2.70691

Image Credits: AI Generated

DOI: 10.1002/cnr2.70691

Keywords: pancreatic cancer, gemcitabine, nab-paclitaxel, biweekly chemotherapy, elderly patients, Phase II trial, unresectable disease, overall response rate, peripheral neuropathy, geriatric assessment, overall survival, oncology

The rationale behind the trial rests on the distinctive metabolic biology of pancreatic tumors. Pancreatic ductal adenocarcinoma is characterized by a dense desmoplastic stroma and a poorly vascularized tumor microenvironment, conditions that limit oxygen and nutrient delivery and force cancer cells to rely heavily on adaptive metabolic pathways. Among these, glutamine metabolism occupies a central position. Glutamine serves as a key nitrogen donor for nucleotide synthesis, feeds the tricarboxylic acid cycle through glutaminolysis, and supports glutathione production, which helps tumor cells buffer oxidative stress. In the hypoxic, nutrient-poor setting of a pancreatic tumor, this dependence on glutamine becomes particularly pronounced, which is precisely why investigators have long been interested in manipulating glutamine availability as a therapeutic strategy.

Paradoxically, the GlutaPanc approach involves supplementing patients with l-glutamine rather than depriving tumors of it. The underlying concept draws on pharmacological modulation of glutamine handling in ways that may potentiate chemotherapy. Gemcitabine, a nucleoside analog, competes for cellular transport and activation pathways that intersect with nucleotide metabolism, and intracellular pools influenced by glutamine-dependent de novo synthesis can affect how effectively the drug is incorporated into DNA. By altering the metabolic state of tumor cells, exogenous glutamine may shift the balance of gemcitabine activation and catabolism, potentially increasing the cytotoxic payload delivered to malignant cells while leaving normal tissues comparatively unaffected. Similar metabolic priming strategies have been explored in other malignancies, but pancreatic cancer, with its extreme metabolic stress, offers a particularly compelling testing ground.

The trial design reflected the careful staging typical of early-phase oncology studies. As an open-label, single-arm phase 1 study, GlutaPanc enrolled participants with advanced pancreatic ductal adenocarcinoma who were candidates for first-line treatment with gemcitabine and nab-paclitaxel. Rather than adding a fourth cytotoxic agent, the investigators layered oral l-glutamine supplementation onto the established doublet, escalating the dose of the amino acid to determine how much could be given safely before dose-limiting toxicities emerged. This design allowed the team to characterize the tolerability profile of the triplet in a controlled manner and to define the dose that would be carried forward into larger efficacy studies.

Safety and feasibility were the primary endpoints, and the trial’s central conclusion is that the combination was deliverable in this patient population. Establishing feasibility matters enormously in pancreatic cancer, where patients frequently present with poor performance status, weight loss, and compromised nutritional reserves. Cachexia and malnutrition are near-universal features of advanced disease, and any regimen that adds burden to an already fragile patient population risks being unusable in practice. The finding that l-glutamine could be incorporated without compromising the administration of gemcitabine and nab-paclitaxel therefore addresses a genuine unmet need, because it opens the door to metabolic interventions that do not come at the cost of treatment intensity.

The determination of a recommended phase 2 dose is the practical output that will shape the next stage of clinical development. Phase 1 trials in oncology traditionally escalate a cytotoxic agent until toxicity becomes unacceptable, but studies of metabolic supplements require a more nuanced approach, balancing pharmacological plausibility against tolerability and adherence. By formally defining the dose of l-glutamine to be used in combination with the chemotherapy doublet, the GlutaPanc investigators have created a standardized protocol that future trials can follow, reducing heterogeneity and enabling meaningful comparison of results across studies. This kind of dose-finding groundwork is unglamorous but essential; without it, subsequent efficacy trials risk being uninterpretable.

The broader significance of the trial lies in its position within a growing movement to integrate metabolic therapeutics into mainstream cancer care. For decades, the Warburg effect and its emphasis on glucose consumption dominated thinking about tumor metabolism, but the past fifteen years have seen glutamine emerge as an equally important nutrient axis. Pancreatic cancer cells in particular have been shown in preclinical models to scavenge glutamine and route it into pathways that support redox balance and biomass production. Translating those laboratory observations into clinical benefit has proven difficult, with several glutamine-targeting strategies faltering in trials. GlutaPanc represents a different tack: rather than blocking glutamine utilization with an enzyme or transporter inhibitor, it modulates the metabolic environment pharmacologically in a way that is compatible with existing chemotherapy.

Nab-paclitaxel, the albumin-bound formulation of paclitaxel used in the trial, deserves mention in its own right. When combined with gemcitabine, nab-paclitaxel improved survival in metastatic pancreatic cancer and became a standard first-line option for patients who can tolerate the regimen. The doublet works in part by depleting the tumor stroma and improving drug delivery, effects that complement gemcitabine’s DNA-damaging mechanism. Adding a metabolic modulator to this regimen is conceptually coherent, because the stroma-modulating activity of nab-paclitaxel may partially relieve the nutrient deprivation that drives glutamine dependence in the first place. Understanding how these three components interact at the level of tumor physiology will be an important question for the phase 2 program.

Cautious interpretation remains essential at this stage. Phase 1 trials are designed to answer questions of safety and dosing, not to demonstrate that a new combination prolongs survival, and the GlutaPanc results should be understood as a green light for further study rather than a treatment advance in themselves. Patients and clinicians will need to await randomized phase 2 and ultimately phase 3 data before drawing conclusions about whether l-glutamine supplementation genuinely improves outcomes when added to gemcitabine and nab-paclitaxel. Nonetheless, the trial addresses a disease with desperately limited options, where five-year survival rates remain in the single digits and where even incremental improvements in first-line therapy can translate into meaningful gains for thousands of patients worldwide.

The GlutaPanc trial also highlights the value of rigorously testing biologically motivated ideas in the clinic. Metabolic interventions are often dismissed as nutritional support rather than true therapeutics, yet the systematic dose-finding approach applied here treats l-glutamine with the same methodological seriousness applied to any investigational drug. As the recommended phase 2 dose now moves forward, the oncology community will be watching to see whether manipulating one of cancer’s favorite nutrients can genuinely bend the curve in pancreatic ductal adenocarcinoma, a disease that has stubbornly resisted nearly every therapeutic innovation thrown at it over the past half-century.

Subject of Research: A phase 1 trial evaluating l-glutamine combined with gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma

Article Title: l-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Article References: Gong, J., Muranaka, H., Choi, S. Y., Tighiouart, M., Bhute, S., Aja, E. R., Jacobs, J. P., Stotland, A., Van Eyk, J., Elmadbouh, O. H. M., Edderkaoui, M., Tanaka, S., Furuya, H., Osipov, A., Lorber, J., Billet, S., Morris, A., ten Hoeve-Scott, J., Graeber, T., … Bhowmick, N. A. (2026). l-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Nature Cancer. https://doi.org/10.1038/s43018-026-01225-z

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01225-z

Keywords: pancreatic cancer, l-glutamine, gemcitabine, nab-paclitaxel, phase 1 trial, GlutaPanc, glutamine metabolism, tumor metabolism, clinical trial, oncology, drug combination, pancreatic ductal adenocarcinoma